CYP26B1 and bladder transitional cell carcinoma: Interestingly, high CYP26B1 expression was associated with improved prognosis in BLCA patients treated with immune checkpoint inhibitors (Supplementary figure 3E), highlighting its potential as a biomarker for immunotherapy response.